Champignon Provides Update on Disclosure Review

vancouver skyline

Champignon Brands Inc. (CSE: SHRM) (the “Company”) continues to work with the British Columbia Securities Commission (the “Commission”) to address an ongoing continuous disclosure review.  Since the review was commenced, the Company has arranged for: Filing of business acquisition reports (collectively, the “Business Acquisition Reports”) in connection with the acquisitions of Artisan Growers Ltd., Novo […]

Read More…

Champignon Announces Filing of Business Acquisition Reports and Appointment of Director

champignon brands skyline 2

VANCOUVER, British Columbia, July 24, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) is pleased to announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Copies of the reports are available for […]

Read More…

Champignon Provides Corporate Update

champignon brands skyline 2

VANCOUVER, British Columbia, July 13, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announces the following corporate updates: BCSC Continuous Disclosure Review The Company continues to work with the British Columbia Securities Commission (the “Commission”) to complete its continuous disclosure review. The review relates to the Company’s disclosure […]

Read More…

Champignon Announces Regulatory Review

champignon brands ketamine wellness clinic

VANCOUVER, British Columbia, June 22, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to the Company’s disclosure obligations since it became a reporting issuer on February […]

Read More…

Champignon’s Dr. Mcintyre / Canadian Rapid Treatment Centre of Excellence (CRTCE) Published in Two Peer Reviewed Study Journals

champignon brands skyline 2

CRTCE’s leading academic footprint facility showing significant outcomes in the arena of psychedelic medicine VANCOUVER, British Columbia, June 19, 2020 (GLOBE NEWSWIRE) — Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of […]

Read More…

Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out

champignon brands on toronto skyline

Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, since commencing trading on March 2, 2020 has expanded its initiatives and rapidly executed on such initiatives to position the Company as a leading publicly traded psychedelic medicine company developing […]

Read More…

Champignon Announces Closing of $15 Million Bought Deal Private Placement

champignon brands ketamine wellness clinic

Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce the closing of its previously announced “bought deal” private placement (the “Offering“) of units of the Company (“Units“) for aggregate gross proceeds of $15,000,375 which includes […]

Read More…

Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio

ketamine iv drip bag in hospital

Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular […]

Read More…